The U.S. Food and Drug Administration (FDA) has approved the MagVita transcranial magnetic stimulation (TMS) therapy system for the treatment of major depressive disorder.
The TMS system was developed by MagVenture, a medical device company, established in 2007.
Low operating costs coupled with an easy administration and equal efficacy rates as other cleared devices makes the MagVita TMS Therapy system the optimal choice for both doctors and patients.
The system is recommended for the treatment of major depressive disorder in adult patients who have failed to receive satisfactory improvement from prior antidepressant medication in the current episode.
The system was the first system to be cleared in the EU and has a proven track-record of treatment efficacy, usability, and quality.
Major depressive disorder is also known as clinical depression, major depression, unipolar depression, or unipolar disorder; or as recurrent depression in the case of repeated episodes.
The disorder is a mental disorder characterized by a pervasive and persistent low mood that is accompanied by low self-esteem and by a loss of interest in normally enjoyable activities.